Dirk Huebner

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus et al. · New England Journal of Medicine · 2017 · 764 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi et al. · The Lancet · 2015 · 734 citations · Full text

Medicine, Immunology, Oncology +15

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Robert Chen, Ajay K. Gopal, Scott E. Smith et al. · Blood · 2016 · 395 citations · Full text

Medicine, Oncology, Pharmacology +13

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study

Anas Younes, Joseph M. Connors, Steven I. Park et al. · The Lancet Oncology · 2013 · 270 citations

Medicine, Oncology, Pharmacology +15